

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,

Semicon Park Electronic City, Phase - II,

Hosur Road, Bengaluru, Karnataka 560100 IN

T +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

May 7, 2026

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Press Release on Financial Results for the quarter and year ended March 31, 2026.

Please find enclosed the press release titled “**Biocon Q4FY26 Total Income at Rs 4,569 Cr; EBITDA at Rs 1,073 Cr; Net Profit (before exceptional items) at Rs 179 Cr; FY26 Total Income at Rs 17,270 Cr; EBITDA at Rs 3,798 Cr; Net Profit (before exceptional items) at Rs 436 Cr**” for the quarter and year ended March 31, 2026.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above

Press Release

**Biocon Q4FY26 Total Income at Rs 4,569 Cr
EBITDA at Rs 1,073 Cr; Net Profit (before exceptional items) at Rs 179 Cr
FY26 Total Income at Rs 17,270 Cr; EBITDA at
Rs 3,798 Cr; Net Profit (before exceptional items) at Rs 436 Cr**

Bengaluru, Karnataka, India: May 7, 2026:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal fourth quarter and the financial year ended March 31, 2026.

Q4FY26 | Financial Highlights

**Rs 4,569 Crore
TOTAL INCOME
Up 10%* YoY**

**Rs 4,517 Crore
OPERATING REVENUE
Up 10%* YoY**

**Excluding one-time
generic lenalidomide sales
in Q4FY25*

**Rs 1,073 Crore
EBITDA
Up 29%* YoY**

**23%
EBITDA MARGIN**

**Rs 179 Crore
NET PROFIT
(before exceptional item)
Up 64%* YoY**

**Rs 277 Crore
NET R&D INVESTMENT
8% of Revenue
(ex-Syngene)**

Q4FY26 | Business Segments Revenue


**Rs 2,756 Crore, Up 12% YoY
BIOSIMILARS**

**Rs 847 Crore, Up 13%* YoY
GENERICS**

**Rs 1,037 Crore, Up 2% YoY
CRDMO: Syngene**

**Excluding one-time generic lenalidomide
sales in Q4FY25*

SEGMENTAL REVENUE CONTRIBUTION



Note: Revenue contribution as a % of Revenue from Operations

FY26 | Financial Highlights

Rs 17,270 Crore
TOTAL INCOME
Up 14%[@]

Rs 16,927 Crore
OPERATING REVENUE
Up 13%*

[@]Excluding one-time,
generic lenalidomide sales
in Q4FY25 & adjusted for
BFI divestment gain

Rs 3,798 Crore
EBITDA
Up 25%[@]

22%
EBITDA MARGIN

Rs 436 Crore
NET PROFIT
(before exceptional item)
Up 323%[@]

Rs 982 Crore
NET R&D INVESTMENT
8% of Revenue
(ex-Syngene)


FY26 | Business Segments Revenue

Rs 10,431 Crore, Up 16% YoY
BIOSIMILARS

Rs 3,168 Crore, Up 17%* YoY
GENERICS

Rs 3,739 Crore, Up 3% YoY
RESEARCH SERVICES: Syngene

*Excluding one-time generic lenalidomide
sales in Q4FY25



Note: Revenue contribution as a % of Revenue from Operations

Leadership Comments

“Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration. We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint. We are now focused on profitability enhancement and long-term value creation.” – **Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited**

“FY26 was a pivotal year for Biocon, marked by the successful integration of our biosimilars and generics business to create one unified biopharmaceutical enterprise with greater scale, capability, and reach. Even as we integrated the businesses, Biocon delivered ~200 basis points of EBITDA margin expansion at a consolidated level on a like-to-like basis, driven by an improved product mix and operational excellence. Our biosimilars business recorded 16% YoY growth in revenue and 40% increase in EBITDA, on a like-to-like basis. Growth was led by strong performance in advanced markets and key tender wins across emerging markets. With the integration now complete, we shift gears in fiscal 2027 from the

“Preserve” phase of our strategy to “Consolidate”, as we set up the business for sustainable growth.” –
Shreehas Tambe, CEO & Managing Director, Biocon Limited

“Syngene’s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance. The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. During the year, we continued to invest in new capabilities and emerging modalities such as peptides and ADCs, further strengthening our integrated offering and positioning us for long-term growth.”

– **Peter Bains, CEO & Managing Director, Syngene International Limited**

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q4FY26 & Full Year FY26

In Rs Crore

Particulars	Q4FY26	Q4FY25 (reported)	Q4 FY25 (adjusted)	YoY (%)	FY26	FY25 (reported)	FY25 (adjusted)	YoY (%)
INCOME								
Biosimilars	2,756	2,463	2,463	12	10,431	9,017	9,017	16
Generics	847	1048	748	13*	3,168	3,017	2,717	17*
CRDMO/ Research Services	1,037	1,018	1,018	2	3,739	3,642	3,642	3
Inter-segment	(122)	(112)	(112)	9	(411)	(416)	(416)	(1)
Revenue from operations#	4,517	4,417	4,117	10*	16,927	15,262	14,962	13*
Other income	53	37	37	42	343	1,208	151	127 ¹
Total Income	4,569	4,454	4,154	10*	17,270	16,470	15,113	14 [@]
Net R&D Expenses	277	231	231	20	982	859	859	14
EBITDA	1,073	1,115	834	29*	3,798	4,374	3,036	25 [@]
EBITDA Margins	23%	25%	20%		22%	27%	20%	
PBT (before Exceptional Items^)	328	466	185	77*	851	1,790	452	88 [@]
Net Profit (before Exceptional Items^^)	179	333	109	64*	436	981	103	323 [@]
Net Profit (Reported)	126	344	120	5*	386	1,013	135	186 [@]

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

Notes to financials above:

#Revenue from operations includes licensing income

¹Adjusted for BFI Divestment Gain of Rs 1,057 Cr

*Excluding one-time generic lenalidomide sales in Q4FY25

@Excluding one-time generic lenalidomide sales in Q4FY25 & adjusted for BFI divestment gain

^Exceptional items during Q4FY26 and FY26 amount to Rs (80) crore and Rs (403) crore, respectively

^^Net of tax and minority interest, exceptional items during Q4FY26 and FY26 amounted to Rs. (53) crore and Rs (50) crore respectively, resulting in a Net Profit of Rs 126 crore and Rs 386 crore, respectively

Financial Commentary: Q4FY26

- **Operating Revenue at Rs 4,517 crore, up 10% year-on-year (YoY), after adjusting for one-time generic Lenalidomide sales in Q4FY25.**

- **EBITDA at Rs 1,073 crore.** Adjusted for generic Lenalidomide sales, EBITDA was up **29% YoY**, with a margin of **23%**.
- **Net Profit** (before exceptional items) is **Rs 179 crore**.

Financial Commentary: FY26

- **Operating Revenue at Rs 16,927 crore**, up **13%** year-on-year (YoY), after adjusting for one-time generic Lenalidomide sales in FY25.
- **EBITDA at Rs 3,798 crore.** Adjusted for generic Lenalidomide sales and for BFI divestment gain, EBITDA was up **25% YoY**.
- **EBITDA margin at 22%**, up **200 basis points**, on a like-to-like basis.
- **Net Profit** (before exceptional items) is **Rs 436 crore**.

Dividend for FY26

The Board of Directors has recommended a final dividend of Re. 0.50 per share at the rate of 10% of the face value of the share, for the financial year ending March 31, 2026.

Board Updates

Based on the recommendations of the Nomination & Remuneration Committee, the Board has recommended for approval of the shareholders the appointment of Rajiv Malik, Daniel Bradbury, Peter Piot, Arun Chandavarkar and Nivruti Rai as Independent Directors, each with effect from August 1, 2026, until the conclusion of the Company's 50th AGM to be held in the year 2028. The Board also recommended the appointment of Thomas Roberts as a Non-Executive, Non-Independent Director with effect from August 1, 2026.

All the above appointed Board members have served on the Board of Biocon Biologics.

Management Updates

Shreehas Tambe has taken charge as CEO & Managing Director of Biocon Limited on April 1, 2026, with Kedar Upadhye appointed as Chief Financial Officer.

Awards and Recognitions

- Kiran Mazumdar-Shaw conferred Honorary Doctor of Philosophy in Applied Life Sciences by the Keck Graduate Institute.
- Kiran Mazumdar-Shaw received an Honorary Fellowship of the UK Academy of Medical Sciences.
- Kiran Mazumdar-Shaw conferred with SAHIT Global Icon Award.
- Shreehas Tambe recognized as one of the Most Promising Business Leaders of Asia 2026.

Sustainability / ESG

- Biocon included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.
- Biocon ranked among Businessworld's Top 20 Most Sustainable Companies in India, securing 3rd position in the pharma sector.
- Syngene included in the S&P Global Sustainability Yearbook 2026; was also recognized as an 'Industry Mover'.

Business Highlights

BIOSIMILARS

- **Q4FY26 Revenue from Operations at Rs 2,756 crore**, up **12% YoY**
- **Q4FY26 EBITDA at Rs 720 crore**, up **33%**; representing **EBITDA Margin of 26%**
- **FY26 Revenue from Operations at Rs 10,431 crore**, up **16% YoY**

- **FY26 EBITDA at Rs 2,751 crore, up 40% YoY, adjusted for BFI divestment gain; representing EBITDA Margin of 26%**
- **Served 6.5+ Million Patients (MAT March 2026 basis)^{##}**

^{##}12-month moving annual patient population (April 2025 to March 2026)

Business Performance

The Biosimilars business remained the core growth driver. Operating revenue for Q4FY26 stood at Rs 2,756 crore, up 12% YoY, driven primarily by performance in the Advanced Markets. Recent launches scaled up supporting growth and operating leverage. EBITDA for the quarter stood at Rs 720 crore, up 33% YoY, translating into an EBITDA margin of 26%. Margins in this segment reflected the benefits of improvement in revenue mix as well as operating leverage. R&D investments for the quarter stood at 7% of revenues.

For FY26, Operating revenue and EBITDA grew at 16% and 40% respectively, on a like-to-like basis.

The Company launched Bosaya™ and Aukelso™, the Denosumab biosimilars to Prolia® and Xgeva®, marking a strategic expansion of its biosimilars portfolio in the U.S. It also obtained key approvals, including Health Canada approvals for Denosumab biosimilars, Bosaya™ and Vevzuo™.

GENERICS: APIs & Generic Formulations

- **Q4FY26 Revenue from Operations at Rs 847 Crore, up 13% YoY, after adjusting for one-time generic Lenalidomide supplies in Q4FY25.**
- **Q4FY26 EBITDA at Rs 75 crore. EBITDA margin at 8%, up ~300 basis points QoQ, driven by higher volumes and operating leverage.**
- **FY26 Revenue from Operations at Rs 3,168 Crore, up 17% YoY, adjusted for generic lenalidomide sales.**

Business Performance

Operating revenue stood at Rs 847 crore. Adjusted for one-time generic Lenalidomide supplies in Q4FY25, revenues grew 13% YoY, driven by generic Liraglutide sales in Europe. EBITDA stood at Rs 75 crore with an 8% margin, improving nearly 300 basis points QoQ.

During the quarter, the Company secured U.S. FDA approval for generic Liraglutide, covering both diabetes and weight management indications. For FY26, Generics revenues grew 17% YoY on a like-to-like basis.

CRDMO: Syngene

- **Q4FY26 Revenue from Operations at Rs 1,037 Crore, up 2% YoY**
- **FY26 Revenue from Operations at Rs 3,739 Crore, up 3% YoY**

Business Performance

Syngene's Q4FY26 operating revenue at Rs 1,037 crore were up 2% YoY and 13% QoQ.

FY26 operating revenues stood at Rs 3,739 crore, reflecting a 3% YoY increase. EBITDA margin for the year was 25%, in line with revised full-year guidance.

Syngene completed 14 client and regulatory audits during the quarter, bringing the full-year total to 85.

Note: Biocon in Q1FY26 renamed its Research Services business segment as CRDMO to represent Syngene's business model of a CRO + CMO.

Enclosed: Fact Sheet – with Financials as per IND-AS



About Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: [@bioconlimited](https://twitter.com/bioconlimited) LinkedIn: [Biocon](https://www.linkedin.com/company/biocon)

About Syngene International Ltd.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com . For the Company’s latest Environmental, Social, and Governance (ESG) report, visit [Syngene ESG Report](#).

FOR MORE INFORMATION	
For Media Rumman Ahmed Head – External Communications, Biocon +91 98451 04173 rumman.ahmed@biocon.com	For Investors Prashant Nair Head – Investor Relations, Biocon +91 98200 95476 Prashant.nair@biocon.com

Earnings Call

The management of the Company will host an Earnings Call on **8th May, 2026 at 9:00 AM IST**, over a webcast, where the senior management will discuss the Company's performance and answer questions from participants. Details of the webcast are given below as well as on the Company website www.biocon.com under Investors >> Financial Calendar >> Earnings Call for the period ended March 31, 2026. Transcript of the conference call will be uploaded on the Company website in due course.

Zoom Webinar Details	
Date	8th May, 2026
Time	9:00 AM IST
Join Zoom Webinar	Click here to register to the earnings call

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

BIOCON GROUP

FACT SHEET

March - 2026

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q4 FY 26	Q4 FY 25	Q4 FY 25 Ex-Lena	Variance %	Variance Adj %
INCOME					
Generics	847	1,048	748	-19%	13%
Biosimilars	2,756	2,463	2,463	12%	12%
CRDMO*	1,037	1,018	1,018	2%	2%
Inter-segment	(122)	(112)	(112)	9%	9%
Revenue from operations #	4,517	4,417	4,117	2%	10%
Other income	53	37	37	42%	42%
TOTAL REVENUE	4,569	4,454	4,154	3%	10%
EXPENDITURE					
Material & Power costs	1,514	1,567	1,548	-3%	-2%
Staff costs	854	765	765	12%	12%
Research & Development expenses**	277	231	231	20%	20%
Other expenses	852	776	776	10%	10%
Manufacturing, staff & other expenses	3,496	3,339	3,320	5%	5%
EBITDA	1,073	1,115	834	-4%	29%
Interest & Finance charges	232	212	212	9%	9%
Depreciation & Amortisation	513	436	436	18%	18%
PBT	328	466	185	-30%	77%
Exceptional item	(80)	21	21	-	
PBT	248	487	206	-49%	20%
Taxes	72	24	(33)	200%	-320%
Taxes on exceptional item	(23)	4	4		
NET PROFIT BEFORE MINORITY INTEREST	199	459	235	-57%	-15%
Minority interest	77	109	109	-29%	-29%
Minority interest on exceptional item	(4)	6	6	-	
NET PROFIT FOR THE PERIOD	126	344	120	-63%	5%
EPS Rs.	0.8	2.9	1.0		
NET PROFIT BEFORE EXCEPTIONAL ITEM	179	333	109	-46%	64%
Exceptional item, net of taxes	(53)	11	11		
NET PROFIT FOR THE PERIOD	126	344	120	-63%	5%
# Licensing Income	3	8	8		
* Earlier 'Research Services'					
** Gross Research & Development expenses	277	231	231		

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 26	Q3 FY 26	Variance %
<u>INCOME</u>			
Generics	847	851	-1%
Biosimilars	2,756	2,497	10%
CRDMO*	1,037	917	13%
Inter-segment	(122)	(92)	33%
Revenue from operations #	4,517	4,173	8%
Other income	53	117	-55%
TOTAL REVENUE	4,569	4,290	6%
<u>EXPENDITURE</u>			
Material & Power costs	1,514	1,441	5%
Staff costs	854	821	4%
Research & Development expenses**	277	249	11%
Other expenses	852	828	3%
Manufacturing, staff & other expenses	3,496	3,340	5%
EBITDA	1,073	951	13%
Interest & Finance charges	232	210	10%
Depreciation & Amortisation	513	515	0%
PBT BEFORE EXCEPTIONAL ITEM	328	226	45%
Exceptional item, Net	(80)	(293)	
PBT	248	(68)	-465%
Taxes	72	51	42%
Taxes on exceptional item	(23)	(67)	
NET PROFIT BEFORE MINORITY INTEREST	199	(52)	-483%
Minority interest	77	51	49%
Minority interest on exceptional item	(4)	(247)	-
NET PROFIT FOR THE PERIOD	126	144	-12%
EPS Rs.	0.8	1.1	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	179	124	45%
Exceptional item	(53)	20	
NET PROFIT FOR THE PERIOD	126	144	-12%
<i># Licensing Income</i>	3	24	
<i>* Earlier 'Research Services'</i>			
<i>** Gross Research & Development expenses</i>	277	249	

BIOCON LIMITED (CONSOLIDATED)					(Rs. Crores)
PROFIT & LOSS STATEMENT					
Particulars	FY 26	FY 25	FY 25 Ex-Lena, BFI- divestment gain	Variance %	Variance adj%
INCOME					
Generics	3,168	3,017	2,717	5%	17%
Biosimilars	10,431	9,017	9,017	16%	16%
CRDMO*	3,739	3,642	3,642	3%	3%
Inter-segment	(411)	(416)	(416)	-1%	-1%
Revenue from operations #	16,927	15,262	14,962	11%	13%
Other income	343	1,208	151	-72%	127%
TOTAL REVENUE	17,270	16,470	15,113	5%	14%
EXPENDITURE					
Material & Power costs	6,117	5,575	5,556	10%	10%
Staff costs	3,295	2,944	2,944	12%	12%
Research & Development expenses**	982	859	859	14%	14%
Other expenses	3,077	2,717	2,717	13%	13%
Manufacturing, staff & other expenses	13,472	12,096	12,076	11%	12%
EBITDA	3,798	4,374	3,036	-13%	25%
Interest & Finance charges	990	897	897	10%	10%
Depreciation & Amortisation	1,957	1,687	1,687	16%	16%
PBT BEFORE EXCEPTIONAL ITEM	851	1,790	452	-52%	88%
Exceptional item, Net	(403)	97	97	-	
PBT	448	1,887	549	-76%	-18%
Taxes	176	416	128	-58%	38%
Taxes on exceptional item	(97)	21	21	-	
Deferred tax charge on withdrawal of indexation benefit	-	20	20	-	
NET PROFIT BEFORE MINORITY INTEREST	369	1,429	379	-74%	-3%
Minority interest	239	393	221	-39%	8%
Minority interest on exceptional item	(256)	23	23	-	
NET PROFIT FOR THE PERIOD	386	1,013	135	-62%	186%
EPS Rs.	2.8	8.4	1.1		
NET PROFIT BEFORE EXCEPTIONAL ITEM	436	981	103	-56%	323%
Exceptional item, net of taxes	(50)	32	32		
NET PROFIT FOR THE PERIOD	386	1,013	135	-62%	186%
# Licensing Income	34	34	34		
* Earlier 'Research Services'					
** Gross Research & Development expenses	982	859	859		

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
(Rs Crores)		
Particulars	Mar 31, 2026	Mar 31, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	9,473	8,708
(b) Capital work-in-progress	4,613	4,102
(c) Right-of-use assets	578	604
(d) Goodwill	18,377	16,786
(e) Other intangible assets	8,058	5,865
(f) Intangible assets under development	2,374	4,407
(g) Financial assets		
Investments	1,089	680
Derivative assets	43	187
Other financial assets	596	68
(i) Income tax asset, net	429	371
(j) Deferred tax asset, net	556	258
(k) Other non-current assets	285	475
Non-current assets	46,471	42,511
Current assets		
(a) Inventories	6,086	4,931
(b) Financial assets		
Investments	690	447
Trade receivables	5,987	5,488
Cash and cash equivalents	2,417	3,227
Other bank balances	777	893
Derivative assets	22	96
Other financial assets	315	456
(c) Other current assets	886	748
Current assets	17,180	16,286
TOTAL - ASSETS	63,651	58,797
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	811	600
(b) Other equity	33,221	21,044
Equity attributable to owners of the Company	34,032	21,644
Non-controlling interests	2,590	6,068
Total Equity	36,622	27,712
Non-current liabilities		
(a) Financial liabilities		
Borrowings	10,746	12,405
Lease liabilities	537	539
Derivative liabilities	68	23
Other financial liabilities	555	2,828
(b) Other non-current liabilities	481	337
(c) Provisions	330	261
(d) Deferred tax liability, net	243	358
Non-current liabilities	12,960	16,751
Current liabilities		
(a) Financial liabilities		
Borrowings	4,078	5,350
Lease liabilities	72	67
Trade payables	6,772	6,549
Derivative liabilities	248	46
Other financial liabilities	967	933
(b) Other current liabilities	1,260	1,024
(c) Provisions	256	192
(d) Income tax liability, net	416	173
Current liabilities	14,069	14,334
TOTAL - EQUITY AND LIABILITIES	63,651	58,797